13,441 Shares in Neumora Therapeutics, Inc. (NASDAQ:NMRA) Acquired by Ballentine Partners LLC

Ballentine Partners LLC purchased a new position in shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) in the 3rd quarter, Holdings Channel reports. The firm purchased 13,441 shares of the company’s stock, valued at approximately $178,000.

Several other hedge funds also recently made changes to their positions in the business. Amalgamated Bank grew its stake in shares of Neumora Therapeutics by 472.8% during the 2nd quarter. Amalgamated Bank now owns 2,910 shares of the company’s stock worth $29,000 after acquiring an additional 2,402 shares in the last quarter. Handelsbanken Fonder AB grew its stake in shares of Neumora Therapeutics by 35.0% during the 3rd quarter. Handelsbanken Fonder AB now owns 26,600 shares of the company’s stock worth $351,000 after acquiring an additional 6,900 shares in the last quarter. Quarry LP bought a new position in shares of Neumora Therapeutics during the 2nd quarter worth approximately $98,000. SkyOak Wealth LLC bought a new position in shares of Neumora Therapeutics during the 2nd quarter worth approximately $147,000. Finally, Principal Financial Group Inc. bought a new position in shares of Neumora Therapeutics during the 2nd quarter worth approximately $166,000. 47.65% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on NMRA. Needham & Company LLC reaffirmed a “buy” rating and set a $23.00 price target on shares of Neumora Therapeutics in a research note on Friday, October 18th. HC Wainwright began coverage on shares of Neumora Therapeutics in a report on Tuesday, October 1st. They set a “buy” rating and a $30.00 target price on the stock. Royal Bank of Canada restated an “outperform” rating and set a $29.00 target price on shares of Neumora Therapeutics in a report on Wednesday, September 4th. Finally, Mizuho began coverage on shares of Neumora Therapeutics in a report on Monday, July 8th. They set an “outperform” rating and a $20.00 target price on the stock. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $22.83.

Insiders Place Their Bets

In other Neumora Therapeutics news, insider Robert A. Lenz sold 30,788 shares of Neumora Therapeutics stock in a transaction on Tuesday, September 17th. The shares were sold at an average price of $11.81, for a total transaction of $363,606.28. Following the completion of the transaction, the insider now directly owns 339,205 shares of the company’s stock, valued at $4,006,011.05. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, insider Robert A. Lenz sold 30,788 shares of the business’s stock in a transaction dated Tuesday, September 17th. The shares were sold at an average price of $11.81, for a total value of $363,606.28. Following the completion of the sale, the insider now owns 339,205 shares of the company’s stock, valued at approximately $4,006,011.05. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Matthew K. Fust sold 14,049 shares of the business’s stock in a transaction dated Friday, October 18th. The shares were sold at an average price of $17.03, for a total transaction of $239,254.47. Following the completion of the sale, the director now directly owns 20,100 shares of the company’s stock, valued at approximately $342,303. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 110,538 shares of company stock valued at $1,390,513 over the last ninety days. 26.40% of the stock is currently owned by company insiders.

Neumora Therapeutics Price Performance

NMRA stock opened at $11.73 on Wednesday. The company has a fifty day moving average price of $12.93 and a two-hundred day moving average price of $11.27. Neumora Therapeutics, Inc. has a one year low of $8.33 and a one year high of $21.00. The stock has a market cap of $1.88 billion and a price-to-earnings ratio of -4.58.

Neumora Therapeutics (NASDAQ:NMRA) last released its quarterly earnings data on Tuesday, August 6th. The company reported ($0.37) EPS for the quarter, hitting analysts’ consensus estimates of ($0.37). Research analysts anticipate that Neumora Therapeutics, Inc. will post -1.48 EPS for the current fiscal year.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.